Gut microbiota and clinical response to immune checkpoint inhibitor therapy in patients with advanced cancer.

ABSTRACT:

Background

There is currently no well-accepted consensus on the association between gut microbiota and the response to treatment of immune checkpoint inhibitors (ICIs) in patients with advanced cancer.

Methods

Fecal samples were collected before ICI treatment. Gut microbiota was analyzed using 16 S ribosomal RNA sequencing. We investigated the relationship between the α-diversity of fecal microbiota and patients' clinical outcomes. Microbiota profiles from patients and healthy controls were determined. Pre-treatment serum was examined by cytokine array.

Results

We analyzed 74 patients, including 42 with melanoma, 8 with kidney cancer, 13 with lung cancer, and 11 with other cancers. Combination therapy of anti-PD1 and anti-CTLA-4 was used in 14 patients, and monotherap

SUBMITTER: Chang JW 

PROVIDER: S-EPMC11399570 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature